MCID: SVR005
MIFTS: 49

Severe Pre-Eclampsia malady

Categories: Cardiovascular diseases, Rare diseases

Aliases & Classifications for Severe Pre-Eclampsia

Aliases & Descriptions for Severe Pre-Eclampsia:

Name: Severe Pre-Eclampsia 12 52 14 69
Severe Preeclampsia 12 14
Severe Pre-Eclampsia, Antepartum Condition or Complication 69
Severe Pre-Eclampsia, Postpartum Condition or Complication 69
Severe Pre-Eclampsia, with Delivery 12
Antepartum Severe Pre-Eclampsia 12
Postpartum Severe Pre-Eclampsia 12
Severe Toxemia 69

Classifications:



External Ids:

Disease Ontology 12 DOID:13129
ICD9CM 35 642.50
ICD10 33 O14.1
UMLS 69 C0156669

Summaries for Severe Pre-Eclampsia

Disease Ontology : 12 A pre-eclampsia that has symptom at least one of the following

MalaCards based summary : Severe Pre-Eclampsia, also known as severe preeclampsia, is related to hellp syndrome and pre-eclampsia. An important gene associated with Severe Pre-Eclampsia is HLA-G (Major Histocompatibility Complex, Class I, G), and among its related pathways/superpathways are Embryonic and Induced Pluripotent Stem Cell Differentiation Pathways and Lineage-specific Markers and Interleukin-4 and 13 signaling. The drugs Methyldopa and Remifentanil have been mentioned in the context of this disorder. Affiliated tissues include placenta, endothelial and liver, and related phenotypes are homeostasis/metabolism and cardiovascular system

Related Diseases for Severe Pre-Eclampsia

Diseases in the Eclampsia family:

Pre-Eclampsia Severe Pre-Eclampsia

Diseases related to Severe Pre-Eclampsia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 123)
id Related Disease Score Top Affiliating Genes
1 hellp syndrome 11.4
2 pre-eclampsia 11.0
3 eclampsia 11.0
4 preeclampsia/eclampsia 1 10.3
5 kidney osteogenic sarcoma 10.3 MMP9 VEGFA
6 acrocephalopolydactyly 10.3 ADIPOQ LEP
7 hepatic vascular disease 10.2 LEP MMP9 VEGFA
8 epidermolysis bullosa simplex, sutosomal recessive 2 10.2 MMP9 VCAM1 VEGFA
9 submucous uterine fibroid 10.2 ALB VEGFA
10 histiocytoid hemangioma 10.2 ALB MMP9 VEGFA
11 malignant perineurioma 10.2 ADIPOQ LEP
12 mucinoses 10.2 ADIPOQ LEP VCAM1
13 cortical blindness mental retardation polydactyly 10.2 ADIPOQ LEP VCAM1
14 hyperlipoproteinemia type iv 10.2 ADIPOQ ALB LEP
15 chronic myocardial ischemia 10.2 ALB LEP VCAM1
16 pleural tuberculosis 10.1 LEP PGF VCAM1
17 vulvitis 10.1 LEP PGF VEGFA
18 limb ischemia 10.1 ADIPOQ LEP LEPR
19 diabetic encephalopathy 10.1 ADIPOQ LEP LEPR
20 freiberg's disease 10.1 ALB SERPINC1
21 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.1 ADIPOQ LEP LEPR
22 adrenal adenoma 10.1 ADIPOQ LEP LEPR
23 capillary hemangioma 10.1 ALB SERPINC1 VEGFA
24 peroneal neuropathy 10.1 ADIPOQ ALB LEP
25 antidepressant type abuse 10.1 ADIPOQ LEP PAPPA
26 parameningeal embryonal rhabdomyosarcoma 10.1 PAPPA PGF VEGFA
27 autoimmune-related retinopathy and optic neuropathy 10.1 ADIPOQ MMP9 VCAM1 VEGFA
28 retinitis 10.1
29 cholesteatoma 10.1 ADIPOQ ALB LEP LEPR
30 aminoaciduria 10.1 F5 MMP9
31 mucopolysaccharidosis iii 10.0 ADIPOQ ALB LEP LEPR
32 citrullinemia, type ii, neonatal-onset 10.0 ALB PGF VCAM1 VEGFA
33 hypersensitivity syndrome, carbamazepine-induced 10.0 ALB VEGFA
34 body dysmorphic disorder 10.0 ADIPOQ ALB LEP LEPR
35 blind loop syndrome 10.0 ADIPOQ LEP LEPR
36 lymphoid leukemia 10.0 ADIPOQ ALB LEP LEPR
37 congenital chloride diarrhea 10.0 ALB SERPINC1 VCAM1 VEGFA
38 med13l syndrome 10.0 APOH F5
39 spinocerebellar ataxia 25 10.0 ALB F5 VEGFA
40 endotheliitis 10.0
41 cerebritis 10.0
42 hemolytic anemia 10.0
43 retinal detachment 10.0
44 achard thiers syndrome 10.0 APOH F5
45 cervix small cell carcinoma 9.9 F5 MMP9 VCAM1
46 lung cancer 9.9 APOH F5 HLA-G
47 lubinsky syndrome 9.9 APOH F5
48 meningitis 9.9 ADIPOQ LEP LEPR
49 stt3a-cdg and stt3b-cdg 9.9 F5 SERPINC1
50 supraumbilical midabdominal raphe and facial cavernous hemangiomas 9.9 APOH F5

Graphical network of the top 20 diseases related to Severe Pre-Eclampsia:



Diseases related to Severe Pre-Eclampsia

Symptoms & Phenotypes for Severe Pre-Eclampsia

MGI Mouse Phenotypes related to Severe Pre-Eclampsia:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.33 ADIPOQ ALB APLN APOH F5 HIF1AN
2 cardiovascular system MP:0005385 10.29 LEP LEPR MMP9 PAPPA PGF SERPINC1
3 growth/size/body region MP:0005378 10.22 ADIPOQ APLN F5 HIF1AN LEP LEPR
4 embryo MP:0005380 10.1 APLN F5 LEP LEPR PGF SERPINC1
5 immune system MP:0005387 10.09 ADIPOQ HLA-G LEP LEPR MMP9 PGF
6 liver/biliary system MP:0005370 9.97 ADIPOQ ALB F5 HIF1AN LEP LEPR
7 integument MP:0010771 9.95 PGF VEGFA ADIPOQ F5 LEP LEPR
8 muscle MP:0005369 9.92 ADIPOQ ALB APLN HIF1AN LEP LEPR
9 neoplasm MP:0002006 9.8 PGF VEGFA ADIPOQ ALB LEP LEPR
10 renal/urinary system MP:0005367 9.7 ADIPOQ ALB LEP LEPR MMP9 SERPINC1
11 respiratory system MP:0005388 9.5 ADIPOQ HIF1AN LEP LEPR MMP9 PGF
12 vision/eye MP:0005391 9.17 APLN LEP LEPR MMP9 PGF SERPINC1

Drugs & Therapeutics for Severe Pre-Eclampsia

Drugs for Severe Pre-Eclampsia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 244)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Methyldopa Approved Phase 4 555-30-6 38853
2
Remifentanil Approved Phase 4,Phase 2 132875-61-7 60815
3
Labetalol Approved Phase 4,Phase 2,Phase 3 36894-69-6 3869
4
Magnesium Sulfate Approved, Vet_approved Phase 4,Phase 2,Phase 3 7487-88-9 24083
5
Furosemide Approved, Vet_approved Phase 4,Phase 2 54-31-9 3440
6
Captopril Approved Phase 4 62571-86-2 44093
7
Clonidine Approved Phase 4 4205-90-7 2803
8
Dalteparin Approved Phase 4,Phase 3,Phase 2 9041-08-1
9
Heparin Approved, Investigational Phase 4,Phase 3,Phase 2 9005-49-6 772 46507594
10
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2 50-78-2 2244
11
Acetaminophen Approved Phase 4,Phase 2,Phase 3 103-90-2 1983
12
Ibuprofen Approved Phase 4,Phase 2,Phase 3 15687-27-1 3672
13
Benzocaine Approved Phase 4,Phase 3 1994-09-7, 94-09-7 2337
14
Nifedipine Approved Phase 4,Phase 3 21829-25-4 4485
15
Calcium carbonate Approved Phase 4 471-34-1
16
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4,Phase 3 59-30-3 6037
17
leucovorin Approved, Nutraceutical Phase 4,Phase 3 58-05-9 54575, 6560146 143
18 tannic acid Approved, Nutraceutical Phase 4,Phase 3
19 Antihypertensive Agents Phase 4,Phase 3,Phase 2
20 Analgesics Phase 4,Phase 2,Phase 3
21 Analgesics, Opioid Phase 4,Phase 2
22 Anesthetics Phase 4,Phase 2,Phase 3
23 Anesthetics, General Phase 4,Phase 2
24 Anesthetics, Intravenous Phase 4,Phase 2
25 Central Nervous System Depressants Phase 4,Phase 2,Phase 3
26 Hypnotics and Sedatives Phase 4,Phase 2
27 Narcotics Phase 4,Phase 2
28 Peripheral Nervous System Agents Phase 4,Phase 2,Phase 3,Phase 1
29 calcium channel blockers Phase 4,Phase 3,Phase 2
30 Calcium, Dietary Phase 4,Phase 3,Phase 2,Phase 1
31 Natriuretic Agents Phase 4,Phase 2,Phase 1
32 Adrenergic Agents Phase 4,Phase 3,Phase 2
33 Autonomic Agents Phase 4,Phase 2,Phase 3
34 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
35 Antibodies Phase 4,Phase 2
36 Antibodies, Antiphospholipid Phase 4
37 Anticoagulants Phase 4,Phase 3,Phase 2
38 Hematinics Phase 4,Phase 3
39 Immunoglobulins Phase 4,Phase 2
40 Micronutrients Phase 4,Phase 3
41 Trace Elements Phase 4,Phase 3
42 Vitamin B Complex Phase 4,Phase 3
43 Vitamins Phase 4,Phase 3
44 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3,Phase 2
45 Adrenergic alpha-Antagonists Phase 4,Phase 3,Phase 2
46 Adrenergic Antagonists Phase 4,Phase 3,Phase 2
47 Adrenergic beta-Antagonists Phase 4,Phase 2,Phase 3
48 Vasodilator Agents Phase 4,Phase 3,Phase 2
49 Bone Density Conservation Agents Phase 4,Phase 2
50 Anti-Arrhythmia Agents Phase 4,Phase 2,Phase 3

Interventional clinical trials:

(show top 50) (show all 148)
id Name Status NCT ID Phase
1 Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape) Unknown status NCT01361425 Phase 4
2 Remifentanil for General Anesthesia in Preeclamptics Unknown status NCT00567957 Phase 4
3 Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia Completed NCT01408979 Phase 4
4 A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen Completed NCT02091401 Phase 4
5 Diuretics for Postpartum High Blood Pressure in Preeclampsia Completed NCT02163655 Phase 4
6 Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure Completed NCT01761916 Phase 4
7 Low Molecular Weight Heparin in Recurrent Miscarriage With Negative Antiphospholipid Antibodies Completed NCT01608347 Phase 4
8 Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers Completed NCT01729468 Phase 4
9 Efficacy and Safety of 1 g Vs 2 g Per Hour Intravenous Maintenance Dose of MgSO4 in Women With Severe Pre-eclampsia Recruiting NCT03164304 Phase 4
10 Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features Recruiting NCT02911701 Phase 4
11 Atenativ Effect on Uterine Blood Flow and Preeclampsia Recruiting NCT02278575 Phase 4
12 Early Vascular Adjustments During Hypertensive Pregnancy Recruiting NCT02531490 Phase 4
13 Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy Recruiting NCT01912677 Phase 4
14 The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy Recruiting NCT02891174 Phase 4
15 Low Dose Calcium to Prevent Preeclampsia Recruiting NCT02338687 Phase 4
16 LMWH to Prevent Preeclampsia and Fetal Growth Restriction Terminated NCT00260520 Phase 4
17 Different Schemes of Magnesium Sulfate for Preeclampsia Terminated NCT02396030 Phase 4
18 Carbetocin vs. Oxytocin for Prevention of Postpartum Bleeding in Patients With Severe Preeclampsia Unknown status NCT01382732 Phase 3
19 Treatment of Severe Hypertension During Pre-Eclampsia: A Preliminary Equivalence Study Between Urapidil and Nicardipine Unknown status NCT00409253 Phase 3
20 Randomized Clinical Trial of Labetalol Versus Hydralazine for Severe Hypertension in Obstetric Patients. Unknown status NCT02050529 Phase 2, Phase 3
21 Folic Acid Dosage and Malformations Reduction Unknown status NCT01244347 Phase 3
22 Prevention of Postpartum Hemorrhage in Patients With Severe Preeclampsia Using Carbetocin Versus Misoprostol Completed NCT02086994 Phase 3
23 Magnesium Sulfate During the Postpartum in Women With Severe Preeclampsia Completed NCT02307201 Phase 2, Phase 3
24 Prevention of Maternal and Perinatal Complications by Enoxaparin in Women With Previous Severe Preeclampsia Completed NCT00986765 Phase 3
25 Magnesium Sulfate in Pregnancy and Postpartum Completed NCT02317146 Phase 2, Phase 3
26 Nonsteroidal Antiinflammatory Drugs in Women With Postpartum Pre-eclampsia Completed NCT01988298 Phase 2, Phase 3
27 New Magnesium Sulphate Protocol for Pre-eclampsia Completed NCT01846156 Phase 3
28 High Dose Folic Acid Supplementation Throughout Pregnancy for Preeclampsia Prevention Completed NCT01355159 Phase 3
29 Combined Antioxidant and Preeclampsia Prediction Studies (CAPPS) Completed NCT00135707 Phase 3
30 Hydralazine Versus Labetalol for the Management of Hypertensive Disorders of Pregnancy Completed NCT01538875 Phase 3
31 Low Molecular Weight Heparin and/or Aspirin in Prevention of Habitual Abortion Completed NCT00959621 Phase 3
32 Metformin in Obese Non-diabetic Pregnant Women Completed NCT01273584 Phase 2, Phase 3
33 Protease Inhibitors to Reduce Malaria Morbidity in HIV-Infected Pregnant Women Completed NCT00993031 Phase 3
34 Trial of Progesterone in Twins and Triplets to Prevent Preterm Birth (STTARS) Completed NCT00099164 Phase 3
35 Magnesium Sulphate for Preterm Birth (MASP Study) Recruiting NCT01492608 Phase 3
36 A Randomized Trial of Docosahexaenoic Acid Supplementation During Pregnancy to Prevent Deep Placentation Disorders Recruiting NCT02336243 Phase 3
37 Evaluation of the Efficacy of Citrulline Supplementation on the Delay of Delivery for Women Hospitalized for Pre-eclampsia (CITRUPE) Recruiting NCT02801695 Phase 2, Phase 3
38 The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction) Recruiting NCT02277132 Phase 2, Phase 3
39 Metformin in Women With Type 2 Diabetes in Pregnancy Trial Recruiting NCT01353391 Phase 3
40 The Treatment of Hypertension Associated With Severe Preeclampsia (PE). A Trial of Urapidil Versus Nicardipine Not yet recruiting NCT02558023 Phase 3
41 Progesterone to Enhance the Efficacy and Success of Expectantly Managed Preterm Severe/Superimposed Preeclampsia Not yet recruiting NCT02989025 Phase 3
42 Prospects for the Prevention of Pregnancy-induced Hypertension and Preeclampsia Trial Not yet recruiting NCT02007837 Phase 3
43 L-Arginine Treatment for Severe Vascular Fetal Intrauterine Growth Restriction: a Randomized Double Bind Controlled Trial (L Arginine in IUGR) Terminated NCT00549575 Phase 3
44 Evaluate Azithromycin Plus Chloroquine And Sulfadoxine Plus Pyrimethamine Combinations For Intermittent Preventive Treatment Of Falciparum Malaria Infection In Pregnant Women In Africa Terminated NCT01103063 Phase 3
45 Maternal and Neonatal Outcomes of the Use of Vasopressors to Treat Hypotension During Spinal Anesthesia for Cesarean Withdrawn NCT01451060 Phase 3
46 Labetalol Versus Magnesium Sulfate (MgSO4) for the Prevention of Eclampsia Trial Withdrawn NCT00293735 Phase 2, Phase 3
47 Utility of Tocolytic Therapy for Maintenance Tocolysis in the Management of Threatened Preterm Delivery Withdrawn NCT01796522 Phase 3
48 Rosuvastatin in Order to Induce Preeclampsia Resolution in Severe PET up to 48 Hours Following Delivery Unknown status NCT02314286 Phase 1, Phase 2
49 Efficacy Study of Digibind for Treatment of Severe Preeclampsia Completed NCT00158743 Phase 2
50 Dexmedetomidine vs. Remifentanil for Pre-eclampsia During Caesarean Delivery Completed NCT01766089 Phase 2

Search NIH Clinical Center for Severe Pre-Eclampsia

Genetic Tests for Severe Pre-Eclampsia

Anatomical Context for Severe Pre-Eclampsia

MalaCards organs/tissues related to Severe Pre-Eclampsia:

39
Placenta, Endothelial, Liver, Lung, Pancreas, Nk Cells, Pituitary

Publications for Severe Pre-Eclampsia

Articles related to Severe Pre-Eclampsia:

(show top 50) (show all 308)
id Title Authors Year
1
Re: Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. J. Ambrozic, G. Brzan Simenc, K. Prokselj, N. Tulz, M. Cvijic and M. Lucovnik. Ultrasound Obstet Gynecol 2017; 49: 104-109. ( 28058788 )
2017
2
Lung and cardiac ultrasound for hemodynamic monitoring of patients with severe pre-eclampsia. ( 27736042 )
2017
3
Assessment of quality of care among in-patients with postpartum haemorrhage and severe pre-eclampsia at st. Francis hospital nsambya: a criteria-based audit. ( 28086822 )
2017
4
Prospective assessment of neurodevelopment in children following a pregnancy complicated by severe pre-eclampsia. ( 27388354 )
2016
5
Serious maternal complications in relation to severe pre-eclampsia: a retrospective cohort study of the impact of hospital volume. ( 27770512 )
2016
6
Ibuprofen versus acetaminophen as a post-partum analgesic for women with severe pre-eclampsia: randomized clinical study. ( 27384376 )
2016
7
Antenatal corticosteroid therapy for foetal maturation in women with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania. ( 27543098 )
2016
8
Cardiac arrest during emergency cesarean section for severe pre-eclampsia and peripartum cardiomyopathy. ( 26927264 )
2016
9
Author's reply re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study. ( 27531337 )
2016
10
Re: Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case control study: Effect of timing of extracorporeal membrane oxygenation during HELLP syndrome. ( 27531338 )
2016
11
Ovarian reserve in women with a previous history of severe pre-eclampsia. ( 27604242 )
2016
12
Antiphospholipid antibodies and the risk of severe and non-severe pre-eclampsia: the NOHA case-control study. ( 26782635 )
2016
13
Antiretrovirals causing severe pre-eclampsia. ( 27939465 )
2016
14
Relation between Helicobacter pylori infection and severe pre-eclampsia complicated by intrauterine growth restriction in a rural area in Egypt. ( 27624279 )
2016
15
Expression of the complement system's activation factors in plasma of patients with early/late-onset severe pre-eclampsia. ( 27461873 )
2016
16
Maternal and neonatal outcomes in women with severe pre-eclampsia undergoing cesarean section: a 10-year retrospective study from a single tertiary care center: anesthetic point of view. ( 26952582 )
2016
17
Maternal cardiac haemodynamics in severe pre-eclampsia complicated by acute pulmonary oedema: A review. ( 27866432 )
2016
18
Oral nifedipine vs. intravenous labetalol for treatment of pregnancy-induced severe pre-eclampsia. ( 27578562 )
2016
19
Risk factors for cardiopulmonary dysfunction in early-onset severe pre-eclampsia. ( 27452610 )
2016
20
Case of soluble fms-like tyrosine kinase 1 apheresis in severe pre-eclampsia developed at 15 weeks' gestation. ( 26094569 )
2015
21
First trimester placental retinol-binding protein 4 (RBP4) and pregnancy-associated placental protein A (PAPP-A) in the prediction of early-onset severe pre-eclampsia. ( 25633269 )
2015
22
Criteria-based audit of quality of care to women with severe pre-eclampsia and eclampsia in a referral hospital in Accra, Ghana. ( 25923663 )
2015
23
Are Meteorological Conditions within the First Trimester of Pregnancy Associated with the Risk of Severe Pre-Eclampsia? ( 26053449 )
2015
24
Complications and maternal mortality from severe pre-eclampsia during the first 48hours in an intensive care unit in Morocco. ( 25638711 )
2015
25
Transthoracic echocardiographic assessment of haemodynamics in severe pre-eclampsia and HIV in South Africa. ( 25891669 )
2015
26
Association between decreased plasma levels of soluble human leukocyte antigen-G and severe pre-eclampsia. ( 26352061 )
2015
27
Vascular endothelial growth factor (VEGF)-634G/C polymorphism was associated with severe pre-eclampsia and lower serum VEGF level. ( 26486233 )
2015
28
Expression of markers of endoplasmic reticulum stress-induced apoptosis in the placenta of women with early and late onset severe pre-eclampsia. ( 25675914 )
2015
29
[40-OR]: A causal model of magnesium sulphate use in women hospitalized at <29 weeks with severe or non-severe pre-eclampsia. ( 25787390 )
2015
30
Severe pre-eclampsia complicated by HELLP syndrome alterations in the structure of the umbilical cord (morphometric and immunohistochemical study). ( 26019650 )
2015
31
Characteristics and outcomes of patients with eclampsia and severe pre-eclampsia in a rural hospital in Western Tanzania: a retrospective medical record study. ( 26350344 )
2015
32
Circulating chromosome 19 miRNA cluster microRNAs in pregnant women with severe pre-eclampsia. ( 26224638 )
2015
33
Third-trimester uterine artery Doppler measurement and maternal postpartum outcome among patients with severe pre-eclampsia. ( 26117553 )
2015
34
Cardiac tamponade in pregnancy during the treatment of severe pre-eclampsia: report of a case. ( 24738125 )
2014
35
Microcirculation in women with severe pre-eclampsia and HELLP syndrome: a case-control study. ( 24206102 )
2014
36
Association between an abnormal cerebroplacental ratio and the development of severe pre-eclampsia. ( 25474554 )
2014
37
Maternal outcomes of magnesium sulphate and diazepam use in women with severe pre-eclampsia and eclampsia in Ethiopia. ( 25035717 )
2014
38
Role of osteoprotegerin gene variants in early-onset severe pre-eclampsia. ( 25256810 )
2014
39
The characteristic of Indonesia's pre-eclampsia: From obstetric intensive care with ventilator until epidemiologic and its molecular biology profile of pulmonary edema in severe pre-eclampsia. ( 26104647 )
2014
40
Abbreviated (12-hour) versus traditional (24-hour) postpartum magnesium sulfate therapy in severe pre-eclampsia. ( 24890747 )
2014
41
2-Methoxyestradiol deficiency is strongly related to hypertension in early onset severe pre-eclampsia. ( 26104608 )
2014
42
Transthoracic echocardiography in women with treated severe pre-eclampsia. ( 24673113 )
2014
43
Coagulation profile in severe pre-eclampsia and eclampsia in ilorin, Nigeria: implications for anaesthetic management in operative obstetrics. ( 25236827 )
2014
44
A novel protocol for postpartum magnesium sulphate in severe pre-eclampsia: a randomized controlled pilot trial. ( 25483417 )
2014
45
Multifaceted intervention to implement indicators of quality of care for severe pre-eclampsia/eclampsia. ( 24268355 )
2014
46
Cytokine production by non-stimulated peripheral blood NK cells and lymphocytes in early-onset severe pre-eclampsia without HELLP. ( 23415844 )
2013
47
Severe pre-eclampsia and hypertensive crises. ( 23962474 )
2013
48
Ultrasonographic Individual Artery Wall Layer Dimensions Indicate Increased Cardiovascular Risk in Previous Severe Pre-eclampsia. ( 24375803 )
2013
49
Decreased levels of folate receptor-I^ and reduced numbers of fetal macrophages (Hofbauer cells) in placentas from pregnancies with severe pre-eclampsia. ( 23480364 )
2013
50
Health system barriers to access and use of magnesium sulfate for women with severe pre-eclampsia and eclampsia in Pakistan: evidence for policy and practice. ( 23555626 )
2013

Variations for Severe Pre-Eclampsia

Expression for Severe Pre-Eclampsia

Search GEO for disease gene expression data for Severe Pre-Eclampsia.

Pathways for Severe Pre-Eclampsia

GO Terms for Severe Pre-Eclampsia

Cellular components related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 ADIPOQ ALB APLN APOH F5 LEP
2 extracellular space GO:0005615 9.4 ADIPOQ ALB APLN APOH F5 LEP
3 platelet alpha granule lumen GO:0031093 9.33 ALB F5 VEGFA

Biological processes related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 angiogenesis GO:0001525 9.78 LEP LEPR PGF VEGFA
2 response to ethanol GO:0045471 9.77 ADIPOQ LEP VCAM1
3 cellular protein metabolic process GO:0044267 9.76 ALB F5 PAPPA SERPINC1
4 glucose homeostasis GO:0042593 9.73 ADIPOQ LEP LEPR
5 female pregnancy GO:0007565 9.7 LEP PAPPA PGF
6 cellular response to vascular endothelial growth factor stimulus GO:0035924 9.61 VCAM1 VEGFA
7 regulation of blood coagulation GO:0030193 9.61 APOH SERPINC1
8 positive regulation of p38MAPK cascade GO:1900745 9.59 LEP VEGFA
9 macrophage differentiation GO:0030225 9.58 MMP9 VEGFA
10 leukocyte tethering or rolling GO:0050901 9.58 LEP VCAM1
11 energy reserve metabolic process GO:0006112 9.57 LEP LEPR
12 platelet degranulation GO:0002576 9.56 ALB APOH F5 VEGFA
13 negative regulation of gluconeogenesis GO:0045721 9.55 ADIPOQ LEPR
14 induction of positive chemotaxis GO:0050930 9.54 PGF VEGFA
15 lactation GO:0007595 9.54 APLN SERPINC1 VEGFA
16 sexual reproduction GO:0019953 9.51 LEP LEPR
17 leptin-mediated signaling pathway GO:0033210 9.49 LEP LEPR
18 regulation of bone remodeling GO:0046850 9.43 LEP LEPR
19 positive regulation of mast cell chemotaxis GO:0060754 9.4 PGF VEGFA
20 negative regulation of vasoconstriction GO:0045906 9.32 APLN LEP
21 response to nutrient GO:0007584 9.26 ADIPOQ LEP SERPINC1 VCAM1
22 bone growth GO:0098868 9.16 LEP LEPR
23 response to hypoxia GO:0001666 9.02 ADIPOQ LEP PGF VCAM1 VEGFA

Molecular functions related to Severe Pre-Eclampsia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 ADIPOQ APLN LEP
2 vascular endothelial growth factor receptor binding GO:0005172 8.96 PGF VEGFA
3 heparin binding GO:0008201 8.92 APOH PGF SERPINC1 VEGFA

Sources for Severe Pre-Eclampsia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....